ACTT-3 will evaluate the combination of interferon beta-1a and remdesivir compared to
remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are
discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For
discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain
safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for
secondary research as well as clinical outcome data. However, infection control or other
restrictions may limit the ability of the subject to return to the clinic. In this case,
these visits may be conducted by phone, and only clinical data will be obtained. The Day 22
visit does not have laboratory tests or collection of samples and is conducted by phone. The
primary outcome is time to recovery by Day 29.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)